Table 5.
Summary of adverse events
| Adverse events | Treatment groups | ||
|---|---|---|---|
| Overproduction | Underexcretion | Combination | |
| (n = 6) | (n = 6) (%) | (n = 6) (%) | |
| All | 0 (0.0%) | 2 (33.3) | 1 (16.7) |
| Nervous system disorders | 0 (0%) | 1 (16.7%) | 0 (0%) |
| Headache | 0 (0.0%) | 1 (16.7) | 0 (0.0) |
| Eye disorders | 0 (0%) | 1 (16.7%) | 0 (0%) |
| Eye pain | 0 (0.0%) | 1 (16.7) | 0 (0.0) |
| Respiratory, thoracic and mediastinal disorders | 0 (0%) | 2 (33.3%) | 0 (0%) |
| Oropharyngeal swelling | 0 (0.0%) | 1 (16.7) | 0 (0.0) |
| Oropharyngeal pain | 0 (0.0%) | 1 (16.7) | 0 (0.0) |
| Gastrointestinal disorders | 0 (0%) | 1 (16.7%) | 0 (0%) |
| Abdominal distension | 0 (0.0%) | 1 (16.7) | 0 (0.0) |
| Abdominal pain | 0 (0.0%) | 1 (16.7) | 0 (0.0) |
| Musculoskeletal and connective tissue disorders | 0 (0%) | 1 (16.7%) | 0 (0%) |
| Neck pain | 0 (0.0%) | 1 (16.7) | 0 (0.0) |
| Investigations | 0 (0%) | 0 (0%) | 1 (16.7%) |
| Alanine aminotransferase increased | 0 (0.0%) | 0 (0.0) | 1 (16.7) |
Incidence (%) = number of patients/number of analyzed patients × 100